Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Kymera Therapeutics (KYMR) Receivables - Other (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Receivables - Other for 6 consecutive years, with $20.0 million as the latest value for Q1 2025.

  • On a quarterly basis, Receivables - Other rose 900.0% to $20.0 million in Q1 2025 year-over-year; TTM through Mar 2025 was $20.0 million, a 900.0% increase, with the full-year FY2024 number at $900000.0, down 76.08% from a year prior.
  • Receivables - Other was $20.0 million for Q1 2025 at Kymera Therapeutics, up from $900000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $20.0 million in Q1 2025 to a low of $135000.0 in Q4 2021.
  • A 5-year average of $3.2 million and a median of $2.2 million in 2022 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: tumbled 76.6% in 2021, then surged 1751.85% in 2022.
  • Kymera Therapeutics' Receivables - Other stood at $135000.0 in 2021, then soared by 1751.85% to $2.5 million in 2022, then skyrocketed by 50.48% to $3.8 million in 2023, then crashed by 76.08% to $900000.0 in 2024, then soared by 2122.22% to $20.0 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Receivables - Other are $20.0 million (Q1 2025), $900000.0 (Q4 2024), and $1.3 million (Q3 2024).